Fazirsiran Reduces Liver Z-AAT Burden by 90% in AATD Disease, Says Dr. Pavel Strnad

Dr. Pavel Strnad discusses pooled phase 2 data indicating that fazirsiran reduces liver Z-AAT burden by approximately 90% in patients with AATD liver disease. He also emphasizes the growing importance of screening for this condition at this stage.

Originally published by gnews